Realty Income Corp vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Realty Income Corp trades at $54.05 (market cap $50.48B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Realty Income Corp is the larger of the two by market cap, and Realty Income Corp pays the higher dividend (6.11%). Which is the better fit depends on your goals — on Pluang, investors hold Realty Income Corp for 127 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| O | RPRX | |
|---|---|---|
Market Cap | $50.48B | $25.27B |
Volume | 6,493,749 | 3,671,183 |
Sector | Real Estate | Health |
52-Week High | $67.56 | $63.96 |
52-Week Low | $53.35 | $35.44 |
Typical Hold Time | 127 Days | 0 Days |
Enterprise Value | $81.11B | $32.50B |
Dividend Yield | 6.11% | 1.66% |
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $54.17, down 0.15% with a bearish technical signal. The stock faces pressure from rising Treasury yields but maintains strong fundamentals including 92.56% gross margins and consistent dividend payments. Recent earnings have missed expectations, though revenue growth continues with 2025 reaching $5.75B. Analyst consensus remains positive with a $64.80 price target despite technical weakness.
The stock offers income potential with its 6%+ dividend yield and 136 consecutive dividend increases, but faces headwinds from interest rate sensitivity and recent earnings misses. Long-term fundamentals remain solid with A-rated credit and near-99% occupancy, though near-term technical pressure suggests cautious entry points.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →